The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats

• Published in: Fundamental & clinical pharmacology 2024-06, Vol.38 (3), p.511-522
• Main Authors: Korkmaz, Yasemin, Dik, Burak
• Format: Article
• Language: English
• Subjects: Adiponectin; Animal models; Animals; Antidiabetics; Benzhydryl Compounds - pharmacology; Beta cells; Blood Glucose - drug effects; Combined treatment; Density; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Experimental - blood; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Type 2 - drug therapy; Dietary supplements; Disease control; Drug Therapy, Combination; Exenatide - pharmacology; Glucosides - administration & dosage; Glucosides - pharmacology; Glycated Hemoglobin - metabolism; High density lipoprotein; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - blood; Insulin Resistance; Leptin; Lipoproteins; Low density lipoprotein; Male; Metabolic disorders; Proteins; Quercetin; Quercetin - pharmacology; Rats; Rats, Wistar; Triglycerides
• ISSN: 0767-3981; 1472-8206
• DOI: 10.1111/fcp.12975

Type 2 diabetes, a metabolic disease that involves extended treatment, is rapidly increasing in humans and animals worldwide. This study aimed to compare monotherapy and combined therapy of exenatide, empagliflozin, and quercetin in 67 Wistar Albino male rats. The animals were divided into the following seven groups: healthy control, diabetes control, diabetes + sham, diabetes + exenatide (10 μg/kg), diabetes + empagliflozin (50 mg/kg), diabetes + quercetin (50 mg/kg), and diabetes + combination treatment. The treatments were continued for 8 weeks. At the end of the experiment, glucose and HbA1c levels decreased with all monotherapy treatments and the combination treatments, while insulin levels increased with exenatide and combined treatments. Adiponectin levels increased with empagliflozin, quercetin, and combined treatments, while leptin levels decreased only with combined treatments. All monotherapies caused an increase in total antioxidant levels. Exenatide and quercetin treatments reduced low-density lipoprotein (LDL) levels; therewithal, exenatide and combined treatments increased high-density lipoprotein (HDL) levels. Triglyceride levels decreased in all treatment groups. The homeostatic model assessment for insulin resistance (HOMA-IR) level decreased with the combined treatment; on the contrary, the homeostatic model assessment for β-cell activity (HOMA-β) level increased with empagliflozin, exenatide, and combined treatments. In conclusion, the antidiabetic effects of exenatide were more pronounced than empagliflozin and quercetin, however, the combined treatment had better antidiabetic and antihyperlipidemic effects than monotherapies. Quercetin could be a supportive or food supplement antidiabetic agent. The exenatide treatment can be recommended for monotherapy in type 2 patients, and the combination of empagliflozin, exenatide, and quercetin may be effective in diabetic patients who need combined therapy.